The FDA has given the green light to a new pill called Zurzuvae, also known as zuranolone, for treating postpartum depression (PPD). This pill, made by Sage Therapeutics and Biogen, is taken once a day for two weeks. Unlike the previous treatment option, which was an injection, this new pill offers a more convenient way to manage PPD.
The symptoms of postpartum depression are similar to other forms of depression, including feelings of sadness, low energy, thoughts of harming oneself, and difficulties in enjoying things. About one in seven women in the US experiences PPD symptoms.
Tiffany Farchione, a psychiatrist at the FDA, mentioned that postpartum depression is a serious condition that can even impact the bond between mother and child, affecting the child's emotional and physical development.
Having an oral medication like Zurzuvae will be very helpful for women dealing with intense and sometimes dangerous emotions associated with PPD. Clinical trials have shown that the pill can significantly reduce depressive symptoms within just three days, and the effects last for up to four weeks after the treatment.
However, there are some side effects to be aware of, such as drowsiness, dizziness, diarrhea, fatigue, and even common cold symptoms. The medication could also affect a person's ability to drive or perform other tasks that require focus, so patients are advised not to drive or use heavy machinery for at least 12 hours after taking it.
It is estimated that one in seven women experience symptoms of PPD in the US, research has found. Research has found.
Sage Therapeutics and Biogen had also wanted to use zuranolone for major depressive disorder (MDD), but the FDA determined that there wasn't enough evidence of its effectiveness for that purpose. The companies are considering their next steps in light of this decision.
It's important to note that postpartum depression is a serious condition, and having a new treatment option like Zurzuvae could provide much-needed relief and support for those who are struggling with it.
